ES2482145T3 - Anticuerpos agonistas contra TSHR - Google Patents

Anticuerpos agonistas contra TSHR Download PDF

Info

Publication number
ES2482145T3
ES2482145T3 ES07732193.3T ES07732193T ES2482145T3 ES 2482145 T3 ES2482145 T3 ES 2482145T3 ES 07732193 T ES07732193 T ES 07732193T ES 2482145 T3 ES2482145 T3 ES 2482145T3
Authority
ES
Spain
Prior art keywords
amino acid
cdr
acid sequence
sequence shown
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07732193.3T
Other languages
English (en)
Spanish (es)
Inventor
Jasvinder-Paul Singh Banga
Jacqueline Ann Gilbert
Deborah Dunn-Walters
Carolyn Padoa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606276A external-priority patent/GB0606276D0/en
Priority claimed from GB0607376A external-priority patent/GB0607376D0/en
Application filed by Kings College London filed Critical Kings College London
Application granted granted Critical
Publication of ES2482145T3 publication Critical patent/ES2482145T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES07732193.3T 2006-03-29 2007-03-29 Anticuerpos agonistas contra TSHR Active ES2482145T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0606276A GB0606276D0 (en) 2006-03-29 2006-03-29 Antibodies
GB0606276 2006-03-29
GB0607376A GB0607376D0 (en) 2006-04-12 2006-04-12 Antibodies
GB0607376 2006-04-12
PCT/GB2007/001139 WO2007110648A1 (en) 2006-03-29 2007-03-29 Agonist antibodies against tshr

Publications (1)

Publication Number Publication Date
ES2482145T3 true ES2482145T3 (es) 2014-08-01

Family

ID=38093407

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07732193.3T Active ES2482145T3 (es) 2006-03-29 2007-03-29 Anticuerpos agonistas contra TSHR

Country Status (5)

Country Link
US (1) US8603466B2 (https=)
EP (1) EP1999153B1 (https=)
JP (1) JP5165672B2 (https=)
ES (1) ES2482145T3 (https=)
WO (1) WO2007110648A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073992B2 (en) * 2008-12-24 2015-07-07 Rsr Ltd. Human anti TSHR antibodies
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
US10711282B2 (en) 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
AU2016382512A1 (en) 2015-12-30 2018-07-12 Novartis Ag Immune effector cell therapies with enhanced efficacy
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
MX2020004229A (es) 2017-10-25 2020-07-22 Novartis Ag Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220227875A1 (en) * 2019-05-31 2022-07-21 University Of Florida Research Foundation, Incorporated Vector-based therapy for thyroid disease
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4330381A1 (en) 2021-04-27 2024-03-06 Novartis AG Viral vector production system
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
US20260015417A1 (en) * 2022-06-10 2026-01-15 Medimabbio Inc. Fusion protein comprising antibody binding specifically to tigit and interleukin-15, and use thereof
CN120112650A (zh) 2022-10-26 2025-06-06 诺华股份有限公司 慢病毒配制品
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
CN118994398A (zh) * 2024-09-27 2024-11-22 兰州大学第二医院 一种抗促甲状腺激素受体单克隆抗体7c3及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69530107T2 (de) * 1994-12-28 2003-10-16 University Of Kentucky, Lexington Monoklonaler anti-idiotypischer antikörper 3h1 aus maus
US20020098190A1 (en) * 1997-06-13 2002-07-25 Malaya Chatterjee Compositions and methods for treating tumors bearing HMFG and CEA antigens
AU6061700A (en) * 1999-07-01 2001-01-22 Procter & Gamble Company, The Transparent or translucent, liquid or gel type automatic dishwashing detergent product
EP1456234B1 (en) * 2001-08-23 2014-04-09 Rsr Limited Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto

Also Published As

Publication number Publication date
EP1999153A1 (en) 2008-12-10
JP2009533021A (ja) 2009-09-17
US20100266493A1 (en) 2010-10-21
JP5165672B2 (ja) 2013-03-21
WO2007110648A1 (en) 2007-10-04
US8603466B2 (en) 2013-12-10
EP1999153B1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
ES2482145T3 (es) Anticuerpos agonistas contra TSHR
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
ES2523740T3 (es) Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
PE20121023A1 (es) Anticuerpos e inmunoconjugados
PE20191102A1 (es) Anticuerpos anti-pd-1 y sus usos
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
EP2471817A3 (en) Humanized antibody molecules specific for IL-31
AR061115A1 (es) Anticuerpos anti- interleuquina 18 (il-18)
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
JP2010536384A5 (https=)
PE20061324A1 (es) Anticuerpos anti-il-6, composiciones, metodos y usos
HRP20130922T1 (hr) U potpunosti humana protutijela protiv humanog 4-1bb (cd137)
PE20131334A1 (es) Anticuerpo igg1 humanizado
CY1115456T1 (el) Μεθοδος χορηγησης αντισωματων αντι-ιl-5
NZ622583A (en) Protein formulations and methods of making same
HRP20211444T1 (hr) Anti-dll3 antitijelo
AR088579A1 (es) Formulaciones de anticuerpos
EP3181585A3 (en) Antigenic gm-csf peptides and antibodies to gm-csf
CL2013003140A1 (es) Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.
ES2625823T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
NZ605980A (en) Anti-fap antibodies and methods of use
PE20110797A1 (es) Anticuerpos anti mn
PE20221151A1 (es) Anticuerpos anti-cd96 y sus metodos de uso